背景:实体瘤在唐氏综合征(DS)患者中的发病率明显降低,包括肺癌.
方法:报道表皮生长因子受体(EGFR)突变的非小细胞肺癌(NSCLC)在DS中的临床表现,并进行文献复习。
结果:在患有DS的个体中,患肺癌的风险明显较低。EGFR突变和EGFR酪氨酸激酶抑制剂(EGFR-TKIs)耐药也存在于肺癌DS中。
结论:临床医生应考虑肺癌DS患者的EGFR突变和EGFR-TKIs耐药。
BACKGROUND: Solid tumors have a markedly decreased incidence in individuals with Down syndrome (DS), including lung cancers.
METHODS: The clinical presentation of epidermal growth factor receptor (EGFR)-mutant non-small-cell lung cancer (NSCLC) in DS was reported and literature on the subject reviewed.
RESULTS: In individuals with DS, the risk of lung cancer appears markedly lower. EGFR mutation and EGFR tyrosine kinase inhibitors (EGFR-TKIs) resistance also exist in DS with lung cancer.
CONCLUSIONS: Clinicians should consider EGFR mutation and EGFR-TKIs resistance in lung cancer patients with DS.